Physician profile
Daniel Ward Mackey
NPI 1407877947
$5,983.44
in general payments reported to CMS, 2019-2025
42 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,128 · 2020: $179 · 2021: $42.59 · 2022: $740 · 2023: $1,314 · 2024: $1,359 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,544 · Education: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,544.47 |
| Education | $350.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $674.36 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $557.06 | 2019-2025 | Imfinzi, Enhertu, Tagrisso |
| Merck Sharp & Dohme LLC | $531.60 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $530.23 | 2019-2025 | Enhertu |
| Glaxosmithkline, LLC. | $369.41 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Novartis Pharmaceuticals Corporation | $354.42 | 2019-2025 | |
| Abbvie INC. | $354.04 | 2023-2025 | |
| Amgen INC. | $306.70 | 2019-2022 | |
| Eisai INC. | $275.20 | 2019-2025 | |
| Gilead Sciences, INC. | $237.73 | 2019-2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $223.89 | 2022-2024 | Tavalisse, Rezlidhia |
| E.R. Squibb & Sons, L.L.C. | $160.39 | 2019-2025 | Opdualag, Opdivo |
| Array Biopharma INC | $136.02 | 2022-2024 | Braftovi, Mektovi, Lorbrena |
| Janssen Biotech, INC. | $134.58 | 2019-2024 | Darzalex, Imbruvica, Erleada |
| Tempus Ai, INC | $127.26 | 2024-2025 | Xt Cdx |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $111.84 | 2019-2023 | Imbruvica, Epkinly |
| Emd Serono, INC. | $98.35 | 2022-2025 | Bavencio |
| Sumitomo Pharma America, INC. | $70.98 | 2024-2025 | Orgovyx |
| Lilly USA, LLC | $66.26 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.99 | 2020-2025 | Gilotrif |
| Astellas Pharma US INC | $46.48 | 2019-2025 | Vyloy |
| Genentech USA, INC. | $45.56 | 2019-2023 | Polivy, Lunsumio, Venclexta |
| Seagen INC. | $43.71 | 2021-2023 | Tukysa |
| Puma Biotechnology, INC. | $41.74 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $37.36 | 2020-2024 | |
| Foundation Medicine, INC. | $34.69 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $34.53 | 2022-2025 | Libtayo |
| Karyopharm Therapeutics INC. | $32.76 | 2025 | Xpovio |
| Incyte Corporation | $32.19 | 2019-2024 | Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $30.73 | 2025 | Iclusig |
| Cti Biopharma Corp. | $29.05 | 2023 | Vonjo |
| Beigene USA, INC. | $27.89 | 2023 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $27.71 | 2022 | |
| Exelixis INC. | $25.81 | 2019-2023 | Cabometyx |
| Genzyme Corporation | $19.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.50 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $15.97 | 2023 | Onivyde, Somatuline Depot |
| Celgene Corporation | $15.13 | 2025 | Opdivo |
| Bausch Health US, LLC | $14.48 | 2021 | |
| Pharmaessentia USA Corporation | $14.38 | 2023 | Besremi |
| Epizyme, INC. | $13.84 | 2022 | |
| Fortovia Therapeutics, INC. | $8.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mackey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.